HomeCompareLLY vs NKE

LLY vs NKE: Dividend Comparison 2026

LLY yields 0.68% · NKE yields 3.07%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NKE wins by $295.6K in total portfolio value
10 years
LLY
LLY
● Live price
0.68%
Share price
$919.77
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.39M
Annual income
$1,080,227.94
Full LLY calculator →
NKE
NKE
● Live price
3.07%
Share price
$52.82
Annual div
$1.62
5Y div CAGR
66.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.68M
Annual income
$1,204,597.17
Full NKE calculator →

Portfolio growth — LLY vs NKE

📍 NKE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLLYNKE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LLY + NKE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LLY pays
NKE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LLY
Annual income on $10K today (after 15% tax)
$57.57/yr
After 10yr DRIP, annual income (after tax)
$918,193.75/yr
NKE
Annual income on $10K today (after 15% tax)
$260.70/yr
After 10yr DRIP, annual income (after tax)
$1,023,907.59/yr
At 15% tax rate, NKE beats the other by $105,713.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LLY + NKE for your $10,000?

LLY: 50%NKE: 50%
100% NKE50/50100% LLY
Portfolio after 10yr
$1.53M
Annual income
$1,142,412.55/yr
Blended yield
74.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NKE right now

LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+35.2% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
NKE
Analyst Ratings
1
Strong
42
Buy
23
Hold
4
Sell
Consensus: Buy
Price Target
$75.35
+42.7% upside vs current
Range: $62.00 — $110.00
Altman Z
3.8
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LLY buys
0
NKE buys
0
No recent congressional trades found for LLY or NKE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLLYNKE
Forward yield0.68%3.07%
Annual dividend / share$6.23$1.62
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%66.3%
Portfolio after 10y$1.39M$1.68M
Annual income after 10y$1,080,227.94$1,204,597.17
Total dividends collected$1.34M$1.62M
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$1,243.95$75.35

Year-by-year: LLY vs NKE ($10,000, DRIP)

YearLLY PortfolioLLY Income/yrNKE PortfolioNKE Income/yrGap
1← crossover$10,835$135.47$11,210$510.05$375.00NKE
2$11,868$274.37$12,883$888.64$1.0KNKE
3$13,261$561.72$15,373$1,587.29$2.1KNKE
4$15,362$1,173.13$19,392$2,943.60$4.0KNKE
5$18,978$2,540.26$26,521$5,771.25$7.5KNKE
6$26,172$5,865.65$40,644$12,267.03$14.5KNKE
7$43,124$15,120.00$72,708$29,218.65$29.6KNKE
8$92,710$46,567.29$159,034$81,236.50$66.3KNKE
9$286,326$187,126.28$446,331$276,164.07$160.0KNKE
10$1,386,597$1,080,227.94$1,682,171$1,204,597.17$295.6KNKE

LLY vs NKE: Complete Analysis 2026

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →

NKEConsumer Discretionary

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells men's, women's, and kids athletic footwear, apparel, equipment, and accessories worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. In addition, it sells a line of performance equipment and accessories comprising bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. The company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel. Additionally, it licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. The company sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

Full NKE Calculator →
📬

Get this LLY vs NKE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LLY vs SCHDLLY vs JEPILLY vs OLLY vs KOLLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.